9,673 results found

The Association for Corporate Growth is having its next Private Equity Regulatory Task Force (PERT) meeting/conference call this Thursday, February 12 at 4:00 p.m. ET.

It's a busy week as Congress and just about everyone else is counting down the days until August recess.

The Senate returns to action this week while the House is out of session.

Last week, the House Financial Services Committee held a hearing on potential JOBS Act 2.0 legislation, including legislation to modernize business development companies (BDCs).

Three major space and defense technology companies secured significant funding rounds in August, with investments totaling over $1.5 billion. The funding activity spans hypersonic defense systems, satellite manufacturing, and orbital computing infrastructure, attracting participation from major financial institutions and venture capital firms.

Taft served as legal counsel to Cincinnati-based private equity firm Ardlussa Capital in successfully closing its first flagship fund at $225 million, exceeding its initial target. The firm specializes in secondary and growth capital investments partnering with emerging managers across the lower middle market in North America and Western Europe.

Don't let those large firms have all of the leverage. You too can be an expert at negotiating an investment bank engagement letter.

As Texas health care organizations, providers, payors, and vendors increasingly adopt and rely on advanced technology to perform various tasks, certain technologies will likely be subject to increased regulatory oversight.

Adalvo has acquired Enzene's romiplostim biosimilar program, which references Amgen's NPLATE® for treating immune thrombocytopenia. The strategic acquisition combines Adalvo's global development and commercial capabilities with Enzene's manufacturing expertise, with Enzene continuing as a development and manufacturing partner for regulatory filings across major international markets.

Due diligence is a critical part of assessing any acquisition. But where the target company is involved in providing healthcare items or services, the U.S. DOJ has given buyers yet another reason to...

CNN senior analyst and best-selling author Jeffrey Toobin will be the keynote speaker at 12th Annual Healthcare and Life Sciences Private Equity and Finance Conference.

How might Oregon's new laws restricting private equity in healthcare operations affect regulations in other states, and what should investors and healthcare providers know about them?

Consumer wearables manufacturer Fitbit announced on February 13 that it is acquiring Twine Health, a "health activation platform" used by employers to manage their workforces' health at the population level.

Formycon AG has announced a strategic manufacturing partnership with OneSource Specialty Pharma Limited to enhance its biosimilar development capabilities. The collaboration brings together Formycon's biosimilar expertise with OneSource's integrated biologics manufacturing platform in Bangalore, India. With three biosimilars already on the U.S. market and four pipeline candidates in development, this partnership aims to strengthen Formycon's position in the competitive biosimilar landscape.

Frazier Healthcare Partners has announced it has closed its 10th private equity fund focused exclusively on the healthcare middle market.

Fresenius has secured exclusive access to 37 biosimilar candidates across 13 therapeutic areas through a strategic development agreement with WuXi Biologics. The partnership positions Fresenius to retain full global commercialization rights and economics for products brought to market. This collaboration spans critical therapeutic areas including oncology, immunology, neurology, and gastroenterology.

Harrow has launched BYOOVIZ (ranibizumab-nuna), the first FDA-approved ophthalmic biosimilar, following an exclusive commercialization agreement with Samsung Bioepis after Biogen's exit from the U.S. market. This marks the beginning of Harrow's partnership to commercialize Samsung Bioepis's ophthalmology biosimilar portfolio, which also includes OPUVIZ, a biosimilar referencing EYLEA.